CN109200293A - A kind of carvacrol solubilising solidification composition and the preparation method and application thereof - Google Patents
A kind of carvacrol solubilising solidification composition and the preparation method and application thereof Download PDFInfo
- Publication number
- CN109200293A CN109200293A CN201811275659.2A CN201811275659A CN109200293A CN 109200293 A CN109200293 A CN 109200293A CN 201811275659 A CN201811275659 A CN 201811275659A CN 109200293 A CN109200293 A CN 109200293A
- Authority
- CN
- China
- Prior art keywords
- carvacrol
- beta
- cyclodextrin
- solubilising
- solution
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
- A61K47/6951—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
- A61K31/05—Phenols
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Medicinal Preparation (AREA)
- Polysaccharides And Polysaccharide Derivatives (AREA)
Abstract
The present invention relates to a kind of carvacrol solubilising solidification compositions and the preparation method and application thereof, the preparation method of the carvacrol solubilising solidification composition includes the following steps: that modified beta-cyclodextrin is dissolved in 50 DEG C of water by (1), obtains clear solution A；(2) by carvacrol and dehydrated alcohol according to volume ratio 1:1, wiring solution-forming B；(3) solution B is added drop-wise in solution A, after keeping 50 DEG C of stirrings 6 hours, is cooled to room temperature and is placed on 4 DEG C of refrigerators after 10 hours, filters, after precipitating is successively washed with water, dehydrated alcohol, be dried in vacuo up to the carvacrol solubilising solidification composition.
Description
Technical field
The invention belongs to pharmaceutical fields, and in particular to a kind of carvacrol solubilising solidification composition and preparation method thereof with answer
With.
Background technique
Carvacrol (Carvacrol) also known as carvacrol, isothymol, be it is a kind of with thymol taste it is colourless extremely
Weak yellow liquid is normally present in volatile oil, thyme volatile oil, Mosla chinensis herb and the camphorwood of plant wild marjoram.It has reported at present
Road, carvacrol have the effects that anti-oxidant, antibacterial, expelling parasite, mitigate rat brain and Reperfusion Injury of Spinal Cord.But due to perfume (or spice)
The disadvantages of celery phenol is not soluble in water, and volatile, oxidizable in air, and stability is poor, greatly affected its bioavilability
And the scope of application.It has been reported that in the prior art and carvacrol and beta-cyclodextrin is prepared into inclusion compound to improve its stability, still
The inclusion rate of the inclusion compound is not high (61.89%), and the dissolubility for the carvacrol that is not significantly improved.The present invention provides a kind of perfume (or spice)
Celery phenol solubilising solidification composition is prepared by carvacrol and modified beta-cyclodextrin, not only inclusion rate be up to 89.4%,
95.2%, and considerably increase the drugloading rate and dissolubility of carvacrol in inclusion compound.
Summary of the invention
The present invention provides a kind of carvacrol solubilising solidification composition, it is characterised in that the carvacrol solubilising solidification group
The preparation method for closing object includes the following steps:
(1) modified beta-cyclodextrin is dissolved in 50 DEG C of water, obtains clear solution A；
(2) by carvacrol and dehydrated alcohol according to volume ratio 1:1, wiring solution-forming B；
(3) solution B is added drop-wise in solution A, after keeping 50 DEG C of stirrings 6 hours, is cooled to room temperature and is placed on 4 DEG C of refrigerators 10
After hour, filtering after precipitating is successively washed with water, dehydrated alcohol, is dried in vacuo and combines up to the carvacrol solubilising solidification
Object.
The mass ratio of modified beta-cyclodextrin and water is 1:3 in step (1)；Every milliliter of solution B instillation changes containing 5g in step (3)
Property beta-cyclodextrin solution A in, it is preferable to use 4 DEG C of water, the washing of 4 DEG C of dehydrated alcohols for the water, dehydrated alcohol washing.
Modified beta-cyclodextrin described in step (1) is selected from beta cyclo dextrin polymer or chitosan graft beta-cyclodextrin；
The preparation method of the beta cyclo dextrin polymer includes the following steps: for beta-cyclodextrin to be dissolved in mass fraction 20%
In sodium hydroxide solution, epoxychloropropane is added at room temperature, after reaction 4 hours, suitable acetone is added and terminates reaction, is used in combination
1mol/L hydrochloric acid tune pH to 7.0, is put into the bag filter of molecular cut off 8000-12000, after dialysis 2 days, is freeze-dried to obtain the final product
Beta cyclo dextrin polymer；The mass ratio of beta-cyclodextrin and sodium hydroxide solution is 1:2, the quality of beta-cyclodextrin and epoxychloropropane
Than for 1:1.
The preparation method of the chitosan graft beta-cyclodextrin includes the following steps: for chitosan to be dissolved in mass fraction 1%
Hydrochloric acid solution in, under stirring, epoxychloropropane is added, is warming up to 85 DEG C, after reaction 5 hours, be cooled to room temperature, filter, will
Filter cake is soluble in water, and potassium carbonate and beta-cyclodextrin is added, and after being heated to reflux temperature reaction 3 hours, is cooled to room temperature, and is added suitable
The acetone of amount terminates reaction, and with 1mol/L hydrochloric acid tune pH7.0, is put into the bag filter of molecular cut off 8000-12000, thoroughly
After analysis 2 days, it is freeze-dried up to chitosan graft beta-cyclodextrin；The mass ratio of chitosan and hydrochloric acid solution is 1:50；Chitosan,
Epoxychloropropane, water, potassium carbonate, beta-cyclodextrin mass ratio be 1:2:50:2:1.
Another embodiment of the present invention provides a kind of preparation method of carvacrol solubilising solidification composition, and feature exists
In including the following steps:
(1) modified beta-cyclodextrin is dissolved in 50 DEG C of water, obtains clear solution A；
(2) by carvacrol and dehydrated alcohol according to volume ratio 1:1, wiring solution-forming B；
(3) solution B is added drop-wise in solution A, after keeping 50 DEG C of stirrings 6 hours, is cooled to room temperature and is placed on 4 DEG C of refrigerators 10
After hour, filtering after precipitating is successively washed with water, dehydrated alcohol, is dried in vacuo and combines up to the carvacrol solubilising solidification
Object.
The mass ratio of modified beta-cyclodextrin and water is 1:3 in step (1)；Every milliliter of solution B instillation changes containing 5g in step (3)
Property beta-cyclodextrin solution A in, it is preferable to use 4 DEG C of water, the washing of 4 DEG C of dehydrated alcohols for the water, dehydrated alcohol washing.
Modified beta-cyclodextrin described in step (1) is selected from beta cyclo dextrin polymer or chitosan graft beta-cyclodextrin；
The preparation method of the beta cyclo dextrin polymer includes the following steps: for beta-cyclodextrin to be dissolved in mass fraction 20%
In sodium hydroxide solution, epoxychloropropane is added at room temperature, after reaction 4 hours, suitable acetone is added and terminates reaction, is used in combination
1mol/L hydrochloric acid tune pH to 7.0, is put into the bag filter of molecular cut off 8000-12000, after dialysis 2 days, is freeze-dried to obtain the final product
Beta cyclo dextrin polymer；The mass ratio of beta-cyclodextrin and sodium hydroxide solution is 1:2, the quality of beta-cyclodextrin and epoxychloropropane
Than for 1:1.
The preparation method of the chitosan graft beta-cyclodextrin includes the following steps: for chitosan to be dissolved in mass fraction 1%
Hydrochloric acid solution in, under stirring, epoxychloropropane is added, is warming up to 85 DEG C, after reaction 5 hours, be cooled to room temperature, filter, will
Filter cake is soluble in water, and potassium carbonate and beta-cyclodextrin is added, and after being heated to reflux temperature reaction 3 hours, is cooled to room temperature, and is added suitable
The acetone of amount terminates reaction, and with 1mol/L hydrochloric acid tune pH7.0, is put into the bag filter of molecular cut off 8000-12000, thoroughly
After analysis 2 days, it is freeze-dried up to chitosan graft beta-cyclodextrin；The mass ratio of chitosan and hydrochloric acid solution is 1:50；Chitosan,
Epoxychloropropane, water, potassium carbonate, beta-cyclodextrin mass ratio be 1:2:50:2:1.
Another embodiment of the present invention provide above-mentioned carvacrol solubilising solidification composition preparation for preventing and/or
Application in the drug for the disease that treatment is mediated by glucokinase.The dosage form of the carvacrol solubilising solidification composition is selected from
Injection, capsule, tablet, oral solution etc..
Another embodiment of the present invention provides above-mentioned carvacrol solubilising solidification composition and is increasing carvacrol solubility
The application of aspect.
Another embodiment of the present invention provides above-mentioned modified beta-cyclodextrin and is preparing carvacrol solubilising solidification composition
In application.It is described to be same as above selected from beta cyclo dextrin polymer or chitosan graft beta-cyclodextrin, preparation method.
Another embodiment of the present invention provides above-mentioned carvacrol solubilising solidification composition and is preparing glucokinase enzyme activity
Application in agent.
Compared with the prior art, the advantages of the present invention are as follows: the present invention has obtained two kinds newly by being modified to beta-cyclodextrin
Type beta cyclo dextrin polymer and glycan graft beta-cyclodextrin, not only inclusion rate is high for the inclusion compound being prepared with carvacrol
(89.4%, 95.2%), and considerably increase the drugloading rate and dissolubility of carvacrol in inclusion compound.
Detailed description of the invention
Fig. 1 is the response diagram that embodiment 1 prepares beta cyclo dextrin polymer；
Fig. 2 is the response diagram that embodiment 2 prepares glycan graft beta-cyclodextrin；
Fig. 3 is the infrared spectrogram of beta cyclo dextrin polymer；
Fig. 4 is the infrared spectrogram of glycan graft beta-cyclodextrin；
Fig. 5 is the outside drawing of product A；
Fig. 6 is the outside drawing of product B.
Specific embodiment
For the ease of a further understanding of the present invention, examples provided below has done more detailed description to it.But
It is that these embodiments are only not supposed to be a limitation to the present invention or implementation principle for better understanding invention, reality of the invention
The mode of applying is not limited to the following contents.
The preparation of 1 beta cyclo dextrin polymer of embodiment
Beta-cyclodextrin (5.0g) is dissolved in the sodium hydroxide solution (10.0g) of mass fraction 20%, ring is added at room temperature
Oxygen chloropropane (5.0g) after reaction 4 hours, is added suitable acetone and terminates reaction, and with 1mol/L hydrochloric acid tune pH to 7.0, puts
In the bag filter for entering molecular cut off 8000-12000, dialysis 2 days after, be freeze-dried white powder (4.86g) is β-ring
Dextrin polymer (by infrared spectroscopy it is found that being grafted successfully).
The preparation of 2 chitosan graft beta-cyclodextrin of embodiment
Chitosan (2.0g) is dissolved in the hydrochloric acid solution (100g) of mass fraction 1%, under stirring, epoxychloropropane is added
(4.0g) is cooled to room temperature, filters after being warming up to 85 DEG C, reaction 5 hours, and filter cake is (100mL) soluble in water, and carbonic acid is added
Potassium (4.0g) and beta-cyclodextrin (2.0g) are cooled to room temperature after being heated to reflux temperature reaction 3 hours, suitable acetone are added
Terminate reaction, and use 1mol/L hydrochloric acid tune pH to 7.0, be put into the bag filter of molecular cut off 8000-12000, dialysis 2 days
Afterwards, it is freeze-dried up to chitosan graft beta-cyclodextrin (3.76g), by infrared spectroscopy it is found that being grafted successfully.
Embodiment 3
(1) beta cyclo dextrin polymer (5.0g) prepared by Example 1 is dissolved in 50 DEG C of water (15.0g), is clarified
Solution A；
(2) carvacrol 0.5mL and dehydrated alcohol 0.5mL mixing wiring solution-forming B are taken；
(3) solution B is added drop-wise in solution A, after keeping 50 DEG C of stirrings 6 hours, is cooled to room temperature and is placed on 4 DEG C of refrigerators 10
After hour, filtering is dried in vacuo after precipitating is successively washed with water (4 DEG C of cold water), dehydrated alcohol (4 DEG C of cold dehydrated alcohols) to obtain the final product
(5.10g measures absorbance at 295nm by ultraviolet specrophotometer, obtains inclusion the carvacrol solubilising solidification composition
Rate is 89.4%, Sheep's-parsley phenol content 8.55%, hereinafter referred to as product A).
Embodiment 4
(1) chitosan graft beta-cyclodextrin (5.0g) prepared by Example 2 is dissolved in 50 DEG C of water (15.0g), is obtained
Clear solution A；
(2) carvacrol 0.5mL and dehydrated alcohol 0.5mL mixing wiring solution-forming B are taken；
(3) solution B is added drop-wise in solution A, after keeping 50 DEG C of stirrings 6 hours, is cooled to room temperature and is placed on 4 DEG C of refrigerators 10
After hour, filtering is dried in vacuo after precipitating is successively washed with water (4 DEG C of cold water), dehydrated alcohol (4 DEG C of cold dehydrated alcohols) to obtain the final product
(5.22g measures absorbance at 295nm by ultraviolet specrophotometer, obtains inclusion the carvacrol solubilising solidification composition
Rate is 95.2%, Sheep's-parsley phenol content 8.90%, hereinafter referred to as product B).
Embodiment 5
(1) in the water (15.0g) for taking beta-cyclodextrin (5.0g) to be dissolved in 50 DEG C, clear solution A is obtained；
(2) carvacrol 0.5mL and dehydrated alcohol 0.5mL mixing wiring solution-forming B are taken；
(3) solution B is added drop-wise in solution A, after keeping 50 DEG C of stirrings 6 hours, is cooled to room temperature and is placed on 4 DEG C of refrigerators 10
After hour, filtering is dried in vacuo after precipitating is successively washed with water (4 DEG C of cold water), dehydrated alcohol (4 DEG C of cold dehydrated alcohols) to obtain the final product
(5.02g measures absorbance at 295nm by ultraviolet specrophotometer to carvacrol inclusion compound, show that inclusion rate is 62.4%, fragrant
Celery phenol content 6.07%, hereinafter referred to as products C).
Embodiment 6
(1) in the water (15.0g) for taking hydroxypropylβ-cyclodextrin (5.0g) to be dissolved in 50 DEG C, clear solution A is obtained；
(2) carvacrol 0.5mL and dehydrated alcohol 0.5mL mixing wiring solution-forming B are taken；
(3) solution B is added drop-wise in solution A, after keeping 50 DEG C of stirrings 6 hours, is cooled to room temperature and is placed on 4 DEG C of refrigerators 10
After hour, filtering is dried in vacuo after precipitating is successively washed with water (4 DEG C of cold water), dehydrated alcohol (4 DEG C of cold dehydrated alcohols) to obtain the final product
(4.93g measures absorbance at 295nm by ultraviolet specrophotometer to carvacrol inclusion compound, show that inclusion rate is 65.6%, fragrant
Celery phenol content 6.49%, hereinafter referred to as product D).
The test of 7 solubilizing effect of embodiment
1.3,1.5,1.7,1.9,2.1,2.3,2.6,3.9,4.2,6.5g product A-D are weighed respectively, and 10mL water is added, fills
Divide dissolution, the results showed that, only product A, B remains to form true solution in the section of 2.1-4.2g；Especially product B is in 6.5g
Also true solution can be formed；Products C, D have reached supersaturation in 2.1g.
8 glucokinase of embodiment (GK) active testing
Product of the present invention A-B and glucokinase (GK) (0.2 unit) are incubated together in test buffer at 25 DEG C
It educates after ten minutes, glucose-6-phosphate dehydrogenase (G6PD) (2.5 unit), ATP (1mM) and glucose (2.5mM) is added.At 30 DEG C
Utilize UV transmittance plate at 340nm with 10 seconds measuring spaces with kinetics model on light absorption microplate reader Spectramax-190
Absorbance 15 minutes.The results show that product A, B show good GK activation effect, EC under 10 μ g/mL concentration50It is small
In 5.0 μ g/mL.
9 dosage form of embodiment
Injection:
It weighs respectively product A, B (200g), 500mL water for injection is added, sufficiently dissolves, refined filtration, filtrate pours into big infusion
In bottle, injection is obtained；
Emulsion:
Oil mutually feeds intake: stearic acid 120g vaseline 66.7g atoleine 93.3mL azone 26.7mL glycerol stearate
Monoesters 66.7g Emulsifier O 404g (200)
Water phase feeds intake: triethanolamine 16mL glycerol 160mL distilled water 546.5mL
Oily phase, water phase are separately heated to 70 DEG C, and oily phased soln is added in product A, B respectively, and oil is mutually slowly added into water phase,
It is fully emulsified, emulsion is made, dispenses spare.
In addition, product A, B, can be prepared by those skilled in the art according to the knowledge in the conventional dose of this field
Other this field common dosage forms such as tablet, capsule.
Claims (10)
1. a kind of carvacrol solubilising solidification composition, it is characterised in that the preparation side of the carvacrol solubilising solidification composition
Method includes the following steps:
(1) modified beta-cyclodextrin is dissolved in 50 DEG C of water, obtains clear solution A；
(2) by carvacrol and dehydrated alcohol according to volume ratio 1:1, wiring solution-forming B；
(3) solution B is added drop-wise in solution A, after keeping 50 DEG C of stirrings 6 hours, is cooled to room temperature and is placed on 4 DEG C of refrigerators 10 hours
Afterwards, it filters, after precipitating is successively washed with water, dehydrated alcohol, is dried in vacuo up to the carvacrol solubilising solidification composition.
2. carvacrol solubilising solidification composition described in claim 1, it is characterised in that in step (1) modified beta-cyclodextrin with
The mass ratio of water is 1:3.
3. the described in any item carvacrol solubilising solidification compositions of claim 1-2, it is characterised in that every milliliter in step (3)
Solution B instills in the solution A of the modified beta-cyclodextrin containing 5g, and the water, it is preferable to use 4 DEG C of water, 4 DEG C of anhydrous second for dehydrated alcohol washing
Alcohol washing.
4. the described in any item carvacrol solubilising solidification compositions of claim 1-3, it is characterised in that step changes described in (1)
Property beta-cyclodextrin be selected from beta cyclo dextrin polymer or chitosan graft beta-cyclodextrin；
The preparation method of the beta cyclo dextrin polymer includes the following steps: the hydrogen-oxygen that beta-cyclodextrin is dissolved in mass fraction 20%
Change in sodium solution, epoxychloropropane is added at room temperature, after reaction 4 hours, suitable acetone is added and terminates reaction, and uses 1mol/L
Hydrochloric acid tune pH to 7.0 is put into the bag filter of molecular cut off 8000-12000, after dialysis 2 days, is freeze-dried up to β-ring paste
Smart polymer；The mass ratio of beta-cyclodextrin and sodium hydroxide solution is 1:2, and the mass ratio of beta-cyclodextrin and epoxychloropropane is 1:
1；
The preparation method of the chitosan graft beta-cyclodextrin includes the following steps: the salt that chitosan is dissolved in mass fraction 1%
In acid solution, under stirring, epoxychloropropane is added, after being warming up to 85 DEG C, reaction 5 hours, is cooled to room temperature, filters, by filter cake
It is soluble in water, potassium carbonate and beta-cyclodextrin is added, after being heated to reflux temperature reaction 3 hours, is cooled to room temperature, is added suitable
Acetone terminate reaction, and use 1mol/L hydrochloric acid tune pH7.0, be put into the bag filter of molecular cut off 8000-12000, dialysis 2 days
Afterwards, it is freeze-dried up to chitosan graft beta-cyclodextrin；The mass ratio of chitosan and hydrochloric acid solution is 1:50；Chitosan, epoxy
Chloropropane, water, potassium carbonate, beta-cyclodextrin mass ratio be 1:2:50:2:1.
5. the preparation method of the described in any item carvacrol solubilising solidification compositions of claim 1-4.
6. the described in any item carvacrol solubilising solidification compositions of claim 1-4 preparation for prevent and/or treat by
Application in the drug for the disease that glucokinase mediates.
7. the described in any item carvacrol solubilising solidification compositions of claim 1-4 are in preparing glucokinase activators
Using.
8. the described in any item applications of claim 6-7, it is characterised in that the dosage form of the carvacrol solubilising solidification composition
Selected from injection, capsule, tablet, oral solution etc..
9. the described in any item carvacrol solubilising solidification compositions of claim 1-4 answering in terms of increasing carvacrol solubility
With.
10. modified beta-cyclodextrin as claimed in claim 4 is preparing the application in carvacrol solubilising solidification composition, feature
It is described selected from beta cyclo dextrin polymer or chitosan graft beta-cyclodextrin.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201811275659.2A CN109200293B (en) | 2018-10-30 | 2018-10-30 | Carvacrol solubilizing and solidifying composition and preparation method and application thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201811275659.2A CN109200293B (en) | 2018-10-30 | 2018-10-30 | Carvacrol solubilizing and solidifying composition and preparation method and application thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN109200293A true CN109200293A (en) | 2019-01-15 |
| CN109200293B CN109200293B (en) | 2021-10-29 |
Family
ID=64997495
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201811275659.2A Active CN109200293B (en) | 2018-10-30 | 2018-10-30 | Carvacrol solubilizing and solidifying composition and preparation method and application thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN109200293B (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN110660645A (en) * | 2019-09-24 | 2020-01-07 | 长春长光圆辰微电子技术有限公司 | Method for cleaning silicon wafer at room temperature |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103478232A (en) * | 2013-09-23 | 2014-01-01 | 浙江省农业科学院 | Carvacrol slow release preservative and preparation method thereof |
| CN105461832A (en) * | 2015-12-31 | 2016-04-06 | 湖北中医药大学 | Cationic beta-cyclodextrin derivative and preparation method and application thereof |
-
2018
- 2018-10-30 CN CN201811275659.2A patent/CN109200293B/en active Active
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103478232A (en) * | 2013-09-23 | 2014-01-01 | 浙江省农业科学院 | Carvacrol slow release preservative and preparation method thereof |
| CN105461832A (en) * | 2015-12-31 | 2016-04-06 | 湖北中医药大学 | Cationic beta-cyclodextrin derivative and preparation method and application thereof |
Non-Patent Citations (3)
| Title |
|---|
| ESTEFÂNIA V. R. CAMPOS等: "Chitosan nanoparticles functionalized with β-cyclodextrin: a promising carrier for botanical pesticides", 《SCIENTIFIC REPORTS》 * |
| K.N.POORNIMA等: "SYNTHESIS AND EVALUATION OF β-CYCLODEXTRIN-EPICHLOROHYDRIN INCLUSION COMPLEX AS A PHARMACEUTICAL EXCIPIENT", 《JOURNAL OF FUNDAMENTAL AND APPLIED SCIENCES》 * |
| 麦云等: "香芹酚对STZ诱导的1型糖尿病小鼠糖脂代谢的影响", 《中国药理学通报》 * |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN110660645A (en) * | 2019-09-24 | 2020-01-07 | 长春长光圆辰微电子技术有限公司 | Method for cleaning silicon wafer at room temperature |
Also Published As
| Publication number | Publication date |
|---|---|
| CN109200293B (en) | 2021-10-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN103462169B (en) | Preparation method of dendrobium nobile beverage | |
| CN103327992B (en) | For prevent or treat inflammatory diseases comprise Caulis Trachelospermi extract and the pharmaceutical composition of Cortex Moutan extract and the method preparing this pharmaceutical composition | |
| DE4221880A1 (en) | Solid and liquid solutions of poorly water-soluble drugs | |
| KR101117861B1 (en) | A forsythoside injection and preparation thereof | |
| KR20100042414A (en) | Composition for enhancing blood circulation containing the extract or fraction of prunus mume as an active ingredient | |
| CN109200293A (en) | A kind of carvacrol solubilising solidification composition and the preparation method and application thereof | |
| EP0849280B1 (en) | Fucans with low molecular weight having anticoagulant, antithrombinic and antithrombotic activity | |
| CN101270101A (en) | Method for preparing potassium sodium dehydroandroan drographolide succinate for injection and its freeze-dried injection | |
| DE69133387T2 (en) | Use of neotrehalose for the manufacture of a medicament for energy supplementation in a living organism | |
| KR20150064417A (en) | Royal jelly beverage composition having improved dispersability in water and method for preparing the same | |
| CN105963247A (en) | Preparation method of injection medicine for improving stability of quercetin medicine injection preparation | |
| CN1939357B (en) | Preparation of Ginkgo Damo injection | |
| AU2021101429A4 (en) | Method for extracting flavonoids as active substances from honey | |
| KR102380162B1 (en) | A pharmaceutical composition for preventing or treating inflammatory bone joint diseases comprising an enzyme-treated royal jelly powder | |
| CN101380102A (en) | Selenium rich pine pollen health food and preparation method thereof | |
| CN111011609A (en) | A composition for enhancing immunity of mammals | |
| CN105999278A (en) | Injecting medicine composition for improving stability of ginsenoside medicine injection | |
| KR101538055B1 (en) | Method for producing Rhus verniciflua extract with urushiol removed and use as herbal acupuncture of Rhus verniciflua extract produced by the same method | |
| CN103705696A (en) | Method for preparing powder injection for treating diabetes by using aloes and Chinese yam | |
| KR101564668B1 (en) | Preparation method for chitosan fermented with herb and its use | |
| DE3341760C2 (en) | ||
| KR880001879B1 (en) | A process for healthy drink | |
| CN105935351A (en) | Medicinal composition for injection, used for improving stability of silymarin medicine injection preparation | |
| CN106389315A (en) | Injection pharmaceutical composition for improving stability of sharpleaf galangal fruit drug injection preparation | |
| CN106109406A (en) | Improve the medicinal composition for injections of breviscapine drug injection preparation stability |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |